Bevacizumab玻璃体腔注射联合手术及激光治疗新生血管性青光眼临床观察.doc

Bevacizumab玻璃体腔注射联合手术及激光治疗新生血管性青光眼临床观察[摘要] 目的：观察玻璃体腔注射Bevacizumab联合小梁切除术及视网膜光凝术治疗新生血管青光眼临床疗效。方法：18例18眼药物及手术不能控制的新生血管青光眼患者行玻璃体腔注射Bevacizumab 0.1 ml/2.5 mg，新生血管消退后行小梁切除术及视网膜光凝术。结果：平均随访6个月，眼压控制完全成功13眼，部分成功4眼，眼压未控制1眼。11眼视力稳定，6眼稍有提高（1眼失访）。结论：玻璃体腔注射Bevacizumab对新生血管青光眼的治疗有降低眼压及辅助手术的积极作用。 [关键词] Bevacizumab；玻璃体腔注射；新生血管青光眼；激光治疗 [中图分类号] R775 [文献标识码]A[文章编号]1674-4721（2011）04（c）-046-02 Clinical observation on the treatment of neovascular glaucoma by intravitreal injection of bevacizumab combined with operation and laser PAN Minmin, LI Shuping, MENG Na, JIAO Yange,YANG Xiaofeng Department of Ophthalmology, Second Affiliated Hospital of Henan Technology Uninversity, Henan province, Luoyang 471000, China [Abstract] objective: To observe the clinical effect of the treatment of neovascular glaucoma by Intravitreal injection of bevacizumab combined with operation and laser. Methods: Intravitreal injection of bevacizumab(0.1 ml/2.5 mg) in 18 eyes of 18 neovascular glaucomas beyond the control of drugs and surgery. Trabeculectomy and retinal photocoagulation were performed after the neovascularization dissipated. The patients were followed up 6 months on average. Results: Intraocular pressure was complete controlled successfully in 13 eyes, partly controlled in 4 eyes, failed to control in 1 eye.The vision of 11 eyes was stable, 6 eyes was slightly improved, while 1 eye was lost to follow. Conclusion: Intravitreal injection of bevacizumab could reduce intraocular pressure and assist operation which had a positive effect on the treatment of neovascular glaucoma. [Key words] Bevacizumab; Intravitreal injection; Neovascular glaucoma；Laser therapy 视网膜静脉阻塞等缺血型视网膜病变严重并发症之一是新生血管性青光眼，常常采取多种治疗手段很难达到满意效果，眼压难以控制，从而引起视力丧失[1-2]。本院采取Bevacizumab玻璃体腔注射联合手术、视网膜光凝治疗新生血管青光眼取得满意效果，为患者减轻了痛苦，现报道如下： 1 资料与方法 1.1 一般资料 收集2008年6月～2010年8月在本院经药物治疗及周边视网膜冷凝复发，眼压无法控制，疼痛症状明显，需手术治疗的视网膜中央静脉阻塞（17眼）及视网膜中央动脉阻塞（1眼）继发新生血管性青光眼患者18例（18只眼）。其中，男性10例（10只眼），女性8例（8只眼）。年龄23～76岁，平均41岁，从发病至发生青光眼时间为1～10个月